
Quarterly report 2022-Q3
added 05-16-2026
Apollo Endosurgery Revenue 2011-2026 | APEN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Apollo Endosurgery
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.9 M | 63 M | 42 M | 50.7 M | 60.9 M | 64.3 M | 64.6 M | 67.8 M | 5.08 M | 7.99 M | 6.69 M | 9.39 M | 7.84 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76.9 M | 5.08 M | 40.6 M |
Quarterly Revenue Apollo Endosurgery
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 19.6 M | 19.3 M | 16.7 M | - | 16.4 M | 16.6 M | 13.9 M | - | 12.8 M | 5.64 M | 10.7 M | - | 11.3 M | 14.3 M | 13.2 M | - | 14.1 M | 15.8 M | 15.7 M | - | 16.5 M | 17.1 M | 14.6 M | - | 23.8 K | 9.24 K | 9.61 K | - | 61.3 K | 748 K | 784 K | - | 1.11 M | 1.33 M | 1.72 M | - | 2.55 M | 2.02 M | 1.11 M | - | 1.42 M | 1.33 M | 2.76 M | - | 1.78 M | 1.54 M | 2.78 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.6 M | 9.24 K | 7.98 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
64.1 M | $ 4.3 | -0.69 % | $ 161 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.29 | -2.97 % | $ 50.5 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.44 | -2.22 % | $ 324 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.01 | - | $ 17.1 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 8.27 | 0.49 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 73.83 | 0.26 % | $ 4.03 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 6.09 | 2.35 % | $ 72.8 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.46 | 0.17 % | $ 28.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 18.37 | -0.33 % | $ 431 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.62 | 0.28 % | $ 535 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 11.02 | -3.76 % | $ 395 M | ||
|
Myomo
MYO
|
40.9 M | $ 1.04 | 9.47 % | $ 43.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.55 | 0.65 % | $ 63.1 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 10.75 | 3.27 % | $ 426 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Profound Medical Corp.
PROF
|
16.1 M | $ 6.83 | -2.01 % | $ 206 M | ||
|
Electromed
ELMD
|
64 M | $ 38.22 | -0.93 % | $ 323 M | ||
|
Butterfly Network
BFLY
|
97.6 M | $ 4.47 | -0.22 % | $ 1.1 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.39 | 3.91 % | $ 6.63 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 84.81 | 0.24 % | $ 11.5 B | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 154.87 | -1.29 % | $ 10.9 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.23 | 0.57 % | $ 1.16 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 43.84 | -2.01 % | $ 1.29 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 89.28 | -0.8 % | $ 3.1 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 85.78 | 3.1 % | $ 50.2 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 68.94 | 0.12 % | $ 2.34 B |